ReviewNPJ precision oncology2018
Liquid biopsy for pediatric central nervous system tumors.
Review in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis.Disease markers · 2019Pooled it
- Extracellular Vesicles in the Biology and Liquid Biopsy Diagnostics of Pediatric High-Grade Glioma - Emerging Findings and Opportunities.Journal of extracellular biology · 2026Review
- Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow-up strategies.Bioengineering & translational medicine · 2026Review
- Case Report: Identification of rareFrontiers in oncology · 2026Article
- Global, regional, and national childhood brain and central nervous system cancer burden: an analysis based on the Global Burden of Disease Study.Tropical medicine and health · 2025Article
- Updates in Diagnostic Techniques and Experimental Therapies for Diffuse Intrinsic Pontine Glioma.Cancers · 2025Review
- The Complexity of Malignant Glioma Treatment.Cancers · 2025Review
- Chromatin accessibility derived from cfDNA serves as a novel classification biomarker of glioma.Frontiers in oncology · 2025Article
- Extracellular Histones Profiles of Pediatric H3K27-Altered Diffuse Midline Glioma.Molecular diagnosis & therapy · 2025Article
- Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid.Clinical epigenetics · 2024Article
- The landscape of current research on pediatric diffuse midline glioma: a quantitative analysis of shifts, leaders, and future avenues.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Long-read sequencing for brain tumors.Frontiers in oncology · 2024Review
- Liquid biopsy: creating opportunities in brain space.British journal of cancer · 2023Review
- Review
- Detection of cell-free histones in the cerebrospinal fluid of pediatric central nervous system malignancies by imaging flow cytometry.Frontiers in molecular biosciences · 2023Article
- Genome-wide analysis of circulating tumor DNA methylation profiles in cerebrospinal fluid: a clinical trial of oncolytic virus for glioblastoma.American journal of cancer research · 2023Article
- Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: Progress and challenges.Neuro-oncology · 2022Article
- Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM).Journal of neuro-oncology · 2022Article
- Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.Neuro-oncology · 2022Article
- The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Central nervous system (CNS) tumors are the most common solid tumors in children, and the leading cause of cancer-related death. Over the past decade, molecular profiling has been incorporated into treatment for pediatric CNS tumors, allowing for a more personalized approach to therapy. Through the identification of tumor-specific changes, it is now possible to diagnose, assign a prognostic subgroup, and develop targeted chemotherapeutic treatment plans for many cancer types. The successful incorporation of informative liquid biopsies, where the liquid biome is interrogated for tumor-associated molecular clues, has the potential to greatly complement the precision-based approach to treatment, and ultimately, to improve clinical outcomes for children with CNS tumors. In this article, the current application of liquid biopsy in cancer therapy will be reviewed, as will its potential for the diagnosis and therapeutic monitoring of pediatric CNS tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.